Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines

NCT03326856
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
botulinum toxin, Type A, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers

NCT04705922
View directory record Official record
Conditions
Healthy
Interventions
TT-00420 Capsule, TT-00420 Tablet
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 31, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

NCT03825341
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Hydroxyurea, Hydroxyurea Oral Capsule
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
9 Months to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 31, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

NCT02525302
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
HT-100
Drug
Lead sponsor
Akashi Therapeutics
Industry
Eligibility
6 Years to 20 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View directory record Official record
Conditions
Varicella, Rubella, Mumps, Measles
Interventions
Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 14 Months
Enrollment
1,851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
141
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 31, 2026, 9:36 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

NCT00829673
View directory record Official record
Conditions
Healthy
Interventions
Dexmethylphenidate Hydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

NCT01756495
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age

NCT00242424
View directory record Official record
Conditions
Inactivated Influenza Vaccine
Interventions
2005-2006 trivalent inactivated influenza vaccine
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
42 Days to 84 Days
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 31, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

NCT03878927
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CPX-351, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

NCT01498692
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Coronary Stent System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

NCT04887506
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions
TAVT-45, Zytiga, Prednisone
Drug
Lead sponsor
Tavanta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 31, 2026, 9:36 AM EDT
Terminated Not applicable Interventional

CuraLin Herbal Supplement for Type 2 Diabetes

NCT05267925
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CuraLin
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

NCT04590040
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Placebo, 15% nano-HAP toothpaste, 5% KNO3 toothpaste
Other · Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

NCT00963508
View directory record Official record
Conditions
Pediculosis
Interventions
Malathion gel 0.5%, Permethrin 1% rinse (Nix Crème)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Hot Springs, Arkansas • Sacramento, California • Kissimmee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of HU6

NCT05433506
View directory record Official record
Conditions
Obese
Interventions
HU6 Tablet, HU6 Capsule
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

NCT00297206
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Month to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Results available

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 31, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

NCT01841489
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 31, 2026, 9:36 AM EDT